Last reviewed · How we verify

lidocaine + epinephrine 1:100,000

Weill Medical College of Cornell University · FDA-approved active Small molecule

lidocaine + epinephrine 1:100,000 is a Local anesthetic with vasoconstrictor Small molecule drug developed by Weill Medical College of Cornell University. It is currently FDA-approved for Local and regional anesthesia for surgical and dental procedures, Infiltration anesthesia for minor surgical procedures, Nerve blocks and epidural anesthesia. Also known as: Xylocaine + epinephrine 1:100,000.

Lidocaine blocks sodium channels to provide local anesthesia, while epinephrine causes vasoconstriction to prolong anesthetic duration and reduce systemic toxicity.

Lidocaine blocks sodium channels to provide local anesthesia, while epinephrine causes vasoconstriction to prolong anesthetic duration and reduce systemic toxicity. Used for Local and regional anesthesia for surgical and dental procedures, Infiltration anesthesia for minor surgical procedures, Nerve blocks and epidural anesthesia.

At a glance

Generic namelidocaine + epinephrine 1:100,000
Also known asXylocaine + epinephrine 1:100,000
SponsorWeill Medical College of Cornell University
Drug classLocal anesthetic with vasoconstrictor
TargetVoltage-gated sodium channels (lidocaine); alpha-1 and beta-1 adrenergic receptors (epinephrine)
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that reversibly inhibits sodium influx in nerve fibers, preventing depolarization and action potential propagation. Epinephrine (1:100,000 concentration) is a vasoconstrictor that reduces blood flow to the injection site, slowing lidocaine absorption into systemic circulation and extending the duration of local anesthesia while minimizing systemic toxicity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about lidocaine + epinephrine 1:100,000

What is lidocaine + epinephrine 1:100,000?

lidocaine + epinephrine 1:100,000 is a Local anesthetic with vasoconstrictor drug developed by Weill Medical College of Cornell University, indicated for Local and regional anesthesia for surgical and dental procedures, Infiltration anesthesia for minor surgical procedures, Nerve blocks and epidural anesthesia.

How does lidocaine + epinephrine 1:100,000 work?

Lidocaine blocks sodium channels to provide local anesthesia, while epinephrine causes vasoconstriction to prolong anesthetic duration and reduce systemic toxicity.

What is lidocaine + epinephrine 1:100,000 used for?

lidocaine + epinephrine 1:100,000 is indicated for Local and regional anesthesia for surgical and dental procedures, Infiltration anesthesia for minor surgical procedures, Nerve blocks and epidural anesthesia.

Who makes lidocaine + epinephrine 1:100,000?

lidocaine + epinephrine 1:100,000 is developed and marketed by Weill Medical College of Cornell University (see full Weill Medical College of Cornell University pipeline at /company/weill-medical-college-of-cornell-university).

Is lidocaine + epinephrine 1:100,000 also known as anything else?

lidocaine + epinephrine 1:100,000 is also known as Xylocaine + epinephrine 1:100,000.

What drug class is lidocaine + epinephrine 1:100,000 in?

lidocaine + epinephrine 1:100,000 belongs to the Local anesthetic with vasoconstrictor class. See all Local anesthetic with vasoconstrictor drugs at /class/local-anesthetic-with-vasoconstrictor.

What development phase is lidocaine + epinephrine 1:100,000 in?

lidocaine + epinephrine 1:100,000 is FDA-approved (marketed).

What are the side effects of lidocaine + epinephrine 1:100,000?

Common side effects of lidocaine + epinephrine 1:100,000 include Injection site reactions (pain, erythema), Transient paresthesia, Headache, Dizziness, Tachycardia (from epinephrine), Hypertension (from epinephrine).

What does lidocaine + epinephrine 1:100,000 target?

lidocaine + epinephrine 1:100,000 targets Voltage-gated sodium channels (lidocaine); alpha-1 and beta-1 adrenergic receptors (epinephrine) and is a Local anesthetic with vasoconstrictor.

Related